FDA may pause approvals if inspections can't happen
What happened
The FDA warned it may delay approving drugs when required facility inspections aren't feasible, signaling a tougher posture on site readiness and compliance documentation. That approach revives inspection‑driven risk management after COVID disruptions and suggests sponsors should expect prioritization of domestic inspections. For companies with global manufacturing, this raises the bar for remote evidence and pre‑inspection readiness to avoid authorization delays. (pharmexec.com)
Why it matters
Two final agency documents — a guidance on what counts as delaying, denying, or limiting an inspection published in June 2024, and a June 26, 2025 guidance that formalizes remote regulatory assessments — together give the Food and Drug Administration explicit legal and operational routes to use remote records and live video reviews while also making clear it can withhold approval when an essential on‑site check cannot be completed. (federalregister.gov) (sidley.com) The agency has signaled it will shift inspection resources and tactics — expanding surprise inspections of foreign facilities and emphasizing risk‑based targeting — while also moving to tools that can substitute for some on‑site activity when travel or access are constrained. (cooley.com) (gao.gov) Remote Regulatory Assessments — defined by the FDA as reviews of an establishment or its records submitted electronically to evaluate compliance — can be either voluntary or mandatory; mandatory RRAs include records requests made under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, which is the statutory authority that lets the agency compel specified records without physically entering a facility. (hhs.gov) (sidley.com) Pre‑approval inspections (called PAIs for drugs and PLIs for biologics) are FDA’s on‑site checks to verify that the manufacturing site and processes can deliver the product claimed in an application; the agency’s guidance and compliance policies say RRAs, remote interactive evaluations (real‑time video walkthroughs), and records requests can sometimes substitute for a PAI or PLI, but where the agency determines those substitutes do not provide sufficient assurance it will insist on an on‑site inspection before completing a regulatory decision. (fda.gov) (hhs.gov) Operational consequences now in plain terms: firms should expect mandatory requests for electronic records and live video demonstrations, a sharper focus on documentary evidence of batch release and test methods (audit trails, validated electronic batch records), and more frequent requests to have subject‑matter experts available for real‑time interviews; refusal to comply with a mandatory RRA or unexplained impediments to inspection can trigger regulatory findings under section 501(j) of the law that deem product adulterated. (sidley.com) (federalregister.gov) The capacity picture underpins timing risk: Government audits show FDA’s investigator capacity has been constrained — the agency reported several hundred domestic and foreign inspections in recent years and GAO recommended strengthening the inspection workforce — meaning limited on‑site inspection availability is a demonstrable factor in approval delays and in the agency’s increased use of remote and risk‑based tools. (gao.gov) (axios.com)
What happens next
- (gao.gov) (axios.com) The FDA warned it may delay approving drugs when required facility inspections aren't feasible, signaling a tougher posture on site readiness and compliance documentation.
- That approach revives inspection‑driven risk management after COVID disruptions and suggests sponsors should expect prioritization of domestic inspections.
Quick answers
What happened in FDA may pause approvals if inspections can't happen?
The FDA warned it may delay approving drugs when required facility inspections aren't feasible, signaling a tougher posture on site readiness and compliance documentation. That approach revives inspection‑driven risk management after COVID disruptions and suggests sponsors should expect prioritization of domestic inspections. For companies with global manufacturing, this raises the bar for remote evidence and pre‑inspection readiness to avoid authorization delays. (pharmexec.com)
Why does FDA may pause approvals if inspections can't happen matter?
Two final agency documents — a guidance on what counts as delaying, denying, or limiting an inspection published in June 2024, and a June 26, 2025 guidance that formalizes remote regulatory assessments — together give the Food and Drug Administration explicit legal and operational routes to use remote records and live video reviews while also making clear it can withhold approval when an essential on‑site check cannot be completed. (federalregister.gov) (sidley.com) The agency has signaled it will shift inspection resources and tactics — expanding surprise inspections of foreign facilities and emphasizing risk‑based targeting — while also moving to tools that can substitute for some on‑site activity when travel or access are constrained. (cooley.com) (gao.gov) Remote Regulatory Assessments — defined by the FDA as reviews of an establishment or its records submitted electronically to evaluate compliance — can be either voluntary or mandatory; mandatory RRAs include records requests made under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, which is the statutory authority that lets the agency compel specified records without physically entering a facility. (hhs.gov) (sidley.com) Pre‑approval inspections (called PAIs for drugs and PLIs for biologics) are FDA’s on‑site checks to verify that the manufacturing site and processes can deliver the product claimed in an application; the agency’s guidance and compliance policies say RRAs, remote interactive evaluations (real‑time video walkthroughs), and records requests can sometimes substitute for a PAI or PLI, but where the agency determines those substitutes do not provide sufficient assurance it will insist on an on‑site inspection before completing a regulatory decision. (fda.gov) (hhs.gov) Operational consequences now in plain terms: firms should expect mandatory requests for electronic records and live video demonstrations, a sharper focus on documentary evidence of batch release and test methods (audit trails, validated electronic batch records), and more frequent requests to have subject‑matter experts available for real‑time interviews; refusal to comply with a mandatory RRA or unexplained impediments to inspection can trigger regulatory findings under section 501(j) of the law that deem product adulterated. (sidley.com) (federalregister.gov) The capacity picture underpins timing risk: Government audits show FDA’s investigator capacity has been constrained — the agency reported several hundred domestic and foreign inspections in recent years and GAO recommended strengthening the inspection workforce — meaning limited on‑site inspection availability is a demonstrable factor in approval delays and in the agency’s increased use of remote and risk‑based tools. (gao.gov) (axios.com)
